Cholesterol, atherosclerotic, and inflammatory risks among patients with statin therapy

N Dai, Y Hu, X Tang, WF Guo, Z Guo, F Zhou… - Cardiovascular …, 2024 - jacc.org
N Dai, Y Hu, X Tang, WF Guo, Z Guo, F Zhou, L Zhang, P Prakash Edavi, H Lu, J Qian, J Ge
Cardiovascular Imaging, 2024jacc.org
Among patients who received statins, in addition to the residual cholesterol risk assessed by
low-density lipoprotein cholesterol (LDL-C), residual atherosclerotic and inflammatory risks
can be evaluated using low-attenuation plaque and pericoronary adipose tissue (PCAT)
attenuation on coronary computed tomography angiography, respectively. When their joint
prognostic values were assessed, low-density lipoprotein cholesterol showed no additional
prognostic value on low-attenuation plaque burden; among patients with high or low …
Among patients who received statins, in addition to the residual cholesterol risk assessed by low-density lipoprotein cholesterol (LDL-C), residual atherosclerotic and inflammatory risks can be evaluated using low-attenuation plaque and pericoronary adipose tissue (PCAT) attenuation on coronary computed tomography angiography, respectively. When their joint prognostic values were assessed, low-density lipoprotein cholesterol showed no additional prognostic value on low-attenuation plaque burden; among patients with high or low lowattenuation plaque burden (LAPB), low-density lipoprotein cholesterol levels did not significantly affect the outcomes. Conversely, when the fat attenuation index (FAI) was added to low-attenuation plaque burden, the prognostic value improved. Patients with high lowattenuation plaque burden and an increased fat attenuation index showed the worst clinical outcomes.
jacc.org
以上显示的是最相近的搜索结果。 查看全部搜索结果